Plain-English translation of NCT06079294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Autoimmune encephalitis is a rare condition where the immune system attacks the brain, causing inflammation and serious neurological problems. This study is testing whether a special type of brain imaging called FDG PET can help doctors diagnose this condition more quickly and accurately than current methods. Researchers will perform these scans early in your illness and again three months after treatment to see how helpful they are.
Currently, doctors rely mainly on MRI scans and blood tests to diagnose autoimmune encephalitis, but these don't always catch the condition early enough. Small previous studies suggest that FDG PET imaging might be better at detecting the brain inflammation caused by this disease, but larger studies are needed to confirm this before it becomes a standard diagnostic tool.
You likely qualify if…
You likely don't qualify if…
You will have two brain imaging scans performed using FDG PET technology. The first scan will happen very early in your illness—either before you start treatment or within 10 days of starting treatment. During the scan, you'll receive an injection of a safe radioactive tracer, then lie still in the imaging machine for about 30 minutes. You'll return for a second scan about 3 months after beginning treatment to see how the inflammation has changed with therapy. You'll also likely have an MRI scan and blood tests as part of standard diagnostic evaluation.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
France
Sponsor
Assistance Publique - Hôpitaux de Paris
Enrollment target
~56 participants
Started
May 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Aurélie Kas, Pr
Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.